

**FOI Request 1132-1819 in relation to Scheduling of Thymosin
The request is for the following:**

"...the request submitted to the TGA for Scheduling of Thymosin Beta 4 and Tb500 as indicated in the link below.

<https://www.tga.gov.au/book-page/27-performance-and-image-enhancing-drugs>.

I am requesting specifically access to the application for inclusion of Thymosin Beta 4 and Tb500 on the Schedules List. I would request all supporting data that was presented in the application that supports the claims.

Any/all clinical and scientific evidence that supports the claims of performance and image enhancement.

Any evidence that supports any medical benefit at all from the use of Thymosin Beta 4 or Tb500.

I would ask for clarification on what appears to be a contradiction in the rationale for the acceptance of the application. The reasons state limited evidence of therapeutic benefits, not registered anywhere in the world (by definition no clinical evidence of efficacy or safety), experimental and yet it is accepted as being performance and image enhancing."

Schedule of Relevant Documents

Doc. No.	Folder Number	Document Number	Author	Addressee	Date	Description	Pages	Decision	Relevant Sections of the Act
1	E19-548637	D19-5424769	Third Party	ACMS #16 November 2015	Nov 2015	Consolidated Agenda paper for ACMS #16 Meeting	20	Release in full	Section 22(1)